XML 58 R43.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Revenue - Additional Information (Details) - USD ($)
1 Months Ended 12 Months Ended
Dec. 31, 2019
Dec. 18, 2015
Feb. 28, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Disaggregation Of Revenue [Line Items]            
Revenue recognized $ 8,500,000     $ (50,624,000)    
Revenue from collaboration agreement       85,071,000 $ 55,663,000 $ 38,448,000
Translational Development Agreements            
Disaggregation Of Revenue [Line Items]            
Term of agreement   4 years        
Agreement termination amount receivable   $ 800,000        
Eligible payments receivable   2,300,000        
Revenue recognized excluding separately negotiated research sequencing contracts       2,300,000 9,300,000 10,000,000.0
Translational Development Agreements | Maximum            
Disaggregation Of Revenue [Line Items]            
Expected revenue through milestone payments   $ 40,000,000.0        
MRD Development Agreements            
Disaggregation Of Revenue [Line Items]            
Milestone revenue recognized       2,000,000.0 10,000,000.0  
Revenue recognized       3,700,000 $ 12,800,000 $ 5,100,000
MRD Development Agreements | Maximum            
Disaggregation Of Revenue [Line Items]            
Additional milestone payment receivable 220,000,000.0     220,000,000.0    
Genentech Collaboration Agreement            
Disaggregation Of Revenue [Line Items]            
Non-refundable upfront payments received     $ 300,000,000.0 300,000,000.0    
Revenue from collaboration agreement       $ 35,100,000    
Genentech Collaboration Agreement | Maximum            
Disaggregation Of Revenue [Line Items]            
Revenue recognition expected period       8 years    
Genentech Collaboration Agreement | Maximum | Regulatory Milestones            
Disaggregation Of Revenue [Line Items]            
Expected revenue through milestone payments 75,000,000.0     $ 75,000,000.0    
Genentech Collaboration Agreement | Maximum | Development Milestones            
Disaggregation Of Revenue [Line Items]            
Expected revenue through milestone payments 300,000,000.0     300,000,000.0    
Genentech Collaboration Agreement | Maximum | Commercial Milestones            
Disaggregation Of Revenue [Line Items]            
Expected revenue through milestone payments 1,430,000,000.0     1,430,000,000.0    
Genentech Collaboration Agreement | Minimum            
Disaggregation Of Revenue [Line Items]            
Expected revenue through milestone payments $ 1,800,000     $ 1,800,000    
Revenue recognition expected period       7 years